New drug combo for HER2+ breast cancer that has spread
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2+ breast cancer that has spread to other parts of the body or cannot be removed by surgery.
- You have had at least 2 but no more than 5 prior treatments for advanced disease (depending on which group you join).
- You have already been treated with trastuzumab deruxtecan (T-DXd) and your cancer got worse (for some groups).
- You are in good enough health to be up and about (ECOG score 0 or 1).
- You do not have serious heart, lung, or eye problems, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This trial tests a new combination of two targeted drugs (patritumab deruxtecan and trastuzumab deruxtecan) for people with hormone receptor-positive breast cancer that has low or ultralow levels of HER2 and has spread or cannot be removed by surgery. The goal is to see if the combination works better than current treatments.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.